RANI RSI Chart
Last 7 days
-17.1%
Last 30 days
-33.4%
Last 90 days
52.5%
Trailing 12 Months
19.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 3.0M | 0 | 0 | 0 |
2023 | 2.1M | 3.0M | 3.4M | 3.3M |
2022 | 2.3M | 2.0M | 1.6M | 1.2M |
2021 | 1.0M | 1.6M | 2.2M | 2.7M |
2020 | 0 | 0 | 0 | 462.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 06, 2023 | imran talat | bought | 22,700 | 2.27 | 10,000 | chief executive officer |
Dec 04, 2023 | imran talat | bought | 12,850 | 2.57 | 5,000 | chief executive officer |
Nov 29, 2023 | imran talat | bought | 41,000 | 2.05 | 20,000 | chief executive officer |
Nov 24, 2023 | south cone investments limited partnership | bought | 10,583,000 | 2.01 | 5,265,160 | - |
Nov 24, 2023 | quiroga cortes isidoro alfonso | sold | -10,583,000 | 2.01 | -5,265,160 | - |
Nov 17, 2023 | butel jean luc | bought | 102,495 | 2.0296 | 50,500 | - |
Nov 16, 2023 | nanavaty maulik | bought | 990 | 1.98 | 500 | - |
Nov 07, 2023 | imran talat | bought | 9,975 | 1.995 | 5,000 | chief executive officer |
May 12, 2023 | south cone investments limited partnership | bought | 10,529 | 3.9809 | 2,645 | - |
May 11, 2023 | south cone investments limited partnership | bought | 10,096 | 3.8683 | 2,610 | - |
Which funds bought or sold RANI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | STATE STREET CORP | unchanged | - | -7,085 | 104,938 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 31,200 | 31,200 | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
May 15, 2024 | UNITED SERVICES AUTOMOBILE ASSOCIATION | unchanged | - | -101,073 | 1,496,840 | 0.04% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | -10,815 | 160,165 | -% |
May 15, 2024 | LASRY MARC | unchanged | - | -13,206 | 195,579 | 0.17% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -46.32 | -3,809 | 3,853 | -% |
May 15, 2024 | Prime Capital Investment Advisors, LLC | reduced | -16.78 | -12,211 | 43,173 | -% |
May 15, 2024 | Alpha Square Group S LLC | reduced | -43.34 | -91,824 | 103,877 | 0.19% |
May 15, 2024 | BARCLAYS PLC | new | - | - | - | -% |
Unveiling Rani Therapeutics Holdings, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Rani Therapeutics Holdings, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Rani Therapeutics Holdings, Inc. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Revenue | -18.7% | 549,000 | 675,000 | 839,000 | 896,000 | 891,000 | 818,000 | 379,000 | 35,000 | 17,500 | - | - | 1,961,000 | 756,000 | 432,000 | 108,000 | 60,000 |
Operating Expenses | 4.5% | 14,034,000 | 13,434,000 | 17,855,000 | 18,294,000 | 16,516,000 | 17,482,000 | 16,342,000 | 15,847,000 | 13,780,000 | 13,362,000 | 27,781,000 | 7,219,000 | 5,954,000 | - | 2,935,000 | 3,450,000 |
S&GA Expenses | -100.0% | - | 5,828,000 | 6,635,000 | 7,208,000 | 6,804,000 | 7,096,500 | 7,239,000 | 6,319,000 | 6,189,000 | 5,945,000 | 15,822,000 | 3,460,000 | 2,607,000 | - | 845,000 | 892,000 |
R&D Expenses | -0.3% | 7,586,000 | 7,606,000 | 11,220,000 | 11,086,000 | 9,712,000 | 10,385,500 | 9,103,000 | 9,528,000 | 7,591,000 | 7,417,000 | 11,959,000 | 3,759,000 | 3,347,000 | - | 2,090,000 | 2,558,000 |
EBITDA Margin | -11.3% | -20.90 | -18.77 | -19.14 | -21.77 | -29.88 | -49.40 | -36.15 | -35.82 | -25.75 | -19.17 | -7.41 | -10.04 | -15.55 | -34.53 | -31.14 | -42.57 |
Interest Expenses | -0.2% | 1,294,000 | 1,296,000 | 1,316,000 | 1,266,000 | 1,207,000 | 719,000 | 352,000 | - | - | -1,000 | 110,000 | 169,000 | 188,000 | - | 64,000 | 2,000 |
Income Taxes | - | - | - | - | - | - | -117,500 | 107,000 | 154,000 | 63,000 | -40,000 | 37,000 | 1,000 | 43,000 | - | 5,000 | 6,000 |
Earnings Before Taxes | 100.0% | - | -14,055,000 | -18,332,000 | -18,664,000 | -16,832,000 | -17,382,500 | -16,315,000 | -15,812,000 | -13,765,000 | -13,345,000 | -28,663,000 | -5,484,000 | -5,555,000 | - | -2,878,000 | -2,708,000 |
EBT Margin | -11.6% | -22.94 | -20.56 | -20.68 | -23.19 | -31.25 | -50.70 | -36.67 | -36.11 | -26.07 | -19.52 | -7.74 | -10.49 | -16.25 | -36.08 | -33.25 | -45.13 |
Net Income | -512.9% | -7,483,000 | 1,812,500 | -9,197,000 | -18,664,000 | -16,832,000 | -812,500 | -7,955,000 | -15,966,000 | -13,828,000 | 352,500 | -3,142,000 | -5,485,000 | -5,598,000 | -5,756,000 | -2,883,000 | -2,714,000 |
Net Income Margin | 12.8% | -11.33 | -12.99 | -13.21 | -14.83 | -19.58 | -30.90 | -23.15 | -16.44 | -9.41 | -5.11 | -9.28 | -12.41 | -16.53 | -36.15 | -43.44 | -67.20 |
Free Cashflow | 25.3% | -9,420,000 | -12,603,000 | -14,824,000 | -12,590,000 | -12,448,000 | -15,159,000 | -12,654,000 | -10,707,000 | -9,614,000 | -11,720,000 | -11,120,000 | -5,764,000 | -4,147,000 | - | 670,000 | -4,937,000 |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q2 | 2020Q4 |
Assets | -7.6% | 54.00 | 58.00 | 70.00 | 84.00 | 96.00 | 108 | 108 | 104 | 115 | 124 | 137 | 77.00 | 78.00 | 79.00 |
Current Assets | -18.6% | 41.00 | 51.00 | 63.00 | 76.00 | 89.00 | 101 | 101 | 98.00 | 109 | 120 | 132 | 69.00 | - | 75.00 |
Cash Equivalents | 25.8% | 7.00 | 6.00 | 5.00 | 8.00 | 19.00 | 27.00 | 27.00 | 97.00 | 108 | 117 | 130 | 69.00 | 0.00 | 73.00 |
Net PPE | -3.3% | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | - | 4.00 |
Liabilities | 20.0% | 39.00 | 32.00 | 36.00 | 35.00 | 35.00 | 34.00 | 22.00 | 6.00 | 5.00 | 3.00 | 5.00 | 10.00 | - | 8.00 |
Current Liabilities | 67.4% | 13.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 5.00 | 9.00 | - | 5.00 |
Long Term Debt | -14.8% | 21.00 | 24.00 | 28.00 | 29.00 | 29.00 | 29.00 | 14.00 | - | - | - | - | - | - | 2.00 |
LT Debt, Current | 75.3% | 9.00 | 5.00 | 1.00 | - | - | - | - | - | - | - | - | 4.00 | - | 1.00 |
LT Debt, Non Current | -100.0% | - | 24.00 | 28.00 | 29.00 | 29.00 | 29.00 | 14.00 | - | - | - | - | - | - | 2.00 |
Shareholder's Equity | 13.0% | 15.00 | 13.00 | 18.00 | 48.00 | 62.00 | 37.00 | 87.00 | 99.00 | 111 | 122 | 132 | 0.00 | 0.00 | - |
Retained Earnings | -10.2% | -80.37 | -72.90 | -65.80 | -56.60 | -47.30 | -38.92 | -30.13 | -22.18 | -14.60 | -8.33 | -3.14 | -125 | - | -114 |
Additional Paid-In Capital | 2.3% | 88.00 | 86.00 | 83.00 | 81.00 | 78.00 | 76.00 | 72.00 | 70.00 | 68.00 | 56.00 | 55.00 | 0.00 | 0.00 | - |
Shares Outstanding | - | 26.00 | - | 26.00 | 25.00 | 25.00 | - | 24.00 | 23.00 | 21.00 | 20.00 | 19.00 | 47.00 | - | - |
Minority Interest | -43.3% | 7.00 | 13.00 | 17.00 | 24.00 | 31.00 | 37.00 | 44.00 | 51.00 | 57.00 | 74.00 | 80.00 | - | - | - |
Float | - | - | - | - | 54.00 | - | - | - | 128 | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 24.4% | -9,402 | -12,436 | -14,345 | -12,255 | -12,200 | -14,629 | -12,198 | -10,328 | -9,360 | -11,449 | -11,120 | -5,628 | -4,048 | - | - | - |
Share Based Compensation | -13.7% | 3,870 | 4,486 | 4,966 | 5,141 | 4,415 | 4,499 | 4,402 | 3,976 | 2,905 | 3,164 | 18,696 | 282 | 453 | - | - | - |
Cashflow From Investing | -22.4% | 10,294 | 13,274 | 11,674 | 789 | 4,123 | -457 | -71,346 | -379 | -254 | -271 | - | -136 | -99.00 | - | - | - |
Cashflow From Financing | 26.0% | 121 | 96.00 | 49.00 | 80.00 | 8.00 | 14,874 | 14,082 | 49.00 | - | -570 | 71,549 | -1,584 | 7,751 | - | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses | ||
Research and development | $ 7,586 | $ 9,712 |
General and administrative | 6,448 | 6,804 |
Total operating expenses | 14,034 | 16,516 |
Loss from operations | (14,034) | (16,516) |
Other income (expense), net | ||
Interest income and other, net | 549 | 891 |
Interest expense and other, net | (1,294) | (1,207) |
Net loss | (14,779) | (16,832) |
Net loss attributable to non-controlling interest | (7,296) | (8,460) |
Net loss attributable to Rani Therapeutics Holdings, Inc. | $ (7,483) | $ (8,372) |
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc.-Basic | $ (0.29) | $ (0.33) |
Net loss per Class A common share attributable to Rani Therapeutics Holding, Inc., diluted | $ (0.29) | $ (0.33) |
Weighted-average share outstanding basic | 26,034 | 25,240 |
Weighted-average share outstanding diluted | 26,034 | 25,240 |
Common Class A [Member] | ||
Other income (expense), net | ||
Net loss attributable to Rani Therapeutics Holdings, Inc. | $ (7,483) | $ (8,372) |
Weighted-average share outstanding basic | 26,034 | 25,240 |
Weighted-average share outstanding diluted | 26,034 | 25,240 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 6,877 | $ 5,864 |
Marketable securities | 32,704 | 42,675 |
Prepaid expenses and other current assets | 1,809 | 2,308 |
Total current assets | 41,390 | 50,847 |
Property and equipment, net | 5,905 | 6,105 |
Operating lease right-of-use asset | 5,971 | 718 |
Other assets | 246 | 246 |
Total assets | 53,512 | 57,916 |
Current liabilities: | ||
Accounts payable | 806 | 648 |
Accrued expenses and other current liabilities | 2,761 | 1,726 |
Current portion of long-term debt | 8,586 | 4,897 |
Current portion of operating lease liability | 1,222 | 718 |
Total current liabilities | 13,375 | 7,989 |
Long-term debt, less current portion | 20,853 | 24,484 |
Operating lease liability, less current portion | 4,749 | 0 |
Total liabilities | 38,977 | 32,473 |
Commitments and contingencies (Note 10) | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2024 and December 31, 2023 | 0 | 0 |
Additional paid-in capital | 87,776 | 85,762 |
Accumulated other comprehensive loss | (11) | (12) |
Accumulated deficit | (80,372) | (72,889) |
Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc. | 7,398 | 12,866 |
Non-controlling interest | 7,137 | 12,577 |
Total stockholders' equity | 14,535 | 25,443 |
Total liabilities and stockholders' equity | 53,512 | 57,916 |
Common Class A [Member] | ||
Stockholders' equity: | ||
Common stock, value | 3 | 3 |
Common Class B [Member] | ||
Stockholders' equity: | ||
Common stock, value | 2 | 2 |
Common Class C [Member] | ||
Stockholders' equity: | ||
Common stock, value | $ 0 | $ 0 |